Search Results
Feb 23, 2026, 12:00 ET New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA
Scientific Founder Professor Chuan He, Ellis Bio's portfolio goes beyond sequencing to provide insights into the DNA and RNA modifications that drive gene expression, collectively known as the epigenome and epitranscriptome. For more information, visit
More news about: Ellis Bio Inc
Feb 23, 2026, 10:30 ET Viral Vectors and Plasmid DNA Manufacturing Market to Reach $34.0 billion by 2033 at 20.4% CAGR: Allied Market Research
for R&D activities, surge in awareness regarding gene therapy, and rise in prevalence of cancer, viral infections, and genetic disorders drive the growth of the global viral vectors and plasmid DNA manufacturing market. However, high cost of gene therapies and risk of mutagenesis and other impediments
More news about: Allied Market Research
Feb 23, 2026, 09:36 ET NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
CLICK HERE.uniQure, headquartered in Amsterdam, the Netherlands, is a biotechnology company focused on the development of gene therapies for severe diseases, including Huntington's disease (HD).The Complaint alleges that during the Class Period, Defendants
More news about: Berger Montague
Feb 23, 2026, 08:01 ET TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, such as miRNA-21, as intracellular assembly templates. This
More news about: TransCode Therapeutics, Inc.
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET Ultima Genomics Introduces the Next Generation of Sequencing at Scale with the Launch of the UG200™ Series and Next Generation Solaris 2.0 Workflows Delivering Higher Output, Better Performance and More Flexible Wafer Configurations
UG 100 fleet in full production, handling over 100,000 whole genome samples a month," said Dr. Arjan Bormans, Chief Scientific Officer of Gene by Gene. "We only started using Ultima's new sample prep and amplification tech late last year, but it's held up - reliable, solid data, and easy to run.
More news about: Ultima Genomics
Feb 23, 2026, 07:00 ET PlantArcBio and Helix Sementes e Biotecnologia (Agroceres Group Company) Announce Licensing Collaboration to Advance High-Yield, Drought-Resilient Corn in South America
agronomic challenges faced by growers."About PlantArcBioPlantArcBio is an ag-biotechnology company developing proprietary gene discovery, gene-editing optimization, and RNAi-based technologies to enhance crop performance and sustainability. Through its patented DIP™ and DIPPER™ platforms,
More news about: PlantArcBio and Agroceres Group
Feb 20, 2026, 10:58 ET Discovery Could Make Immune Checkpoint Inhibitors Safer
healthy cardiac muscle cells as targets in addition to cancer cells. The team went on to show, in mice, that blocking TNF signaling specifically through the TNFR2 gene product prevented the inflammatory cycle from starting in the heart. "Checkpoint inhibitors allow TNF signaling to trigger CD8 T-cells that are
More news about: Cincinnati Children's Hospital Medical Center
Feb 20, 2026, 10:45 ET 'Functional Unemployment' Improves in January; Remains Up Year-Over-Year, Says Ludwig Institute
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
Feb 20, 2026, 10:31 ET Preparative and Process Chromatography Market worth $21.50 billion by 2031 | MarketsandMarkets™
among pharma and biopharma end users. Increased investment in the form of grants and sponsorships has been observed for the development of new cell and gene therapy-based treatments to provide personalized treatments. The increased production of biologics and vaccines is projected to grow the market for
More news about: MarketsandMarkets
Feb 20, 2026, 08:57 ET OCI Rebrands as Apex Geotech Solutions to Reflect Expanded Offering for Foundation Drilling Customers
these businesses together, we've built a scaled, differentiated platform with deep production expertise and broad manufacturing capabilities," said Gene Swindell, President of Apex. "The Apex Geotech Solutions name reflects how customers already engage with us, as one trusted provider delivering critical
More news about: Gemspring Capital
Feb 20, 2026, 08:00 ET Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial
approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). NRG1 gene fusions and other gene fusions are best detected using the combination of tissue-based DNA and RNA next-generation sequencing.For more information on the
More news about: Partner Therapeutics, Inc.
Feb 19, 2026, 20:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Feb 19, 2026, 20:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Feb 19, 2026, 14:47 ET RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Feb 19, 2026, 10:30 ET Veterinary Contract Manufacturing & Research Market worth $9.24 billion by 2031 | MarketsandMarkets™
technologies, specialized expertise, and GMP-compliant facilities that they lack in-house. Their focus on innovative platforms—such as novel biologics, gene-based therapies, advanced formulations, and digital health tools—drives high demand for CDMO and CRO support across early-stage R&D, scale-up, and
More news about: MarketsandMarkets
Feb 19, 2026, 10:15 ET The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Feb 19, 2026, 09:00 ET Merlin CP-GEP Becomes the First and Only Gene Expression Profile (GEP) Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk
Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Cutaneous Melanoma (Version 1.2026), recognizing Merlin CP-GEP¹ (clinicopathologic–gene expression profile test) as the first and only molecular test that may be used in select early-stage melanoma patients. The NCCN Melanoma
More news about: SkylineDx
Feb 19, 2026, 08:30 ET Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
Foundational Patent Strengthens AI Moat Across Multimodal Data Standardization, Disease Stratification and Gene MappingSACRAMENTO, Calif., Feb. 19, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an
More news about: Lunai Bioworks Inc.
Feb 19, 2026, 07:00 ET Montana Renewables and World Energy Join Forces to Drive Efficiency and Scale in Sustainable Aviation Fuel (SAF) Deliveries
agriculture.""Contracting with MRL for SAF production enables us to better support our growing aviation decarbonization business," said World Energy CEO, Gene Gebolys. "We are serving many of the most recognized and respected brands in the world in sectors including tech, pharma, aviation, finance, business
More news about: Calumet, Inc.
Feb 19, 2026, 07:00 ET Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
INS1201, an intrathecally delivered gene therapy for patients with Duchenne muscular dystrophy (DMD).INS1202In January 2026, the Company dosed the first patient in the Phase 1 ARMOR study of INS1202, an intrathecally delivered gene therapy for patients with amyotrophic
More news about: Insmed Incorporated
Feb 19, 2026, 03:30 ET Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
validate CaV2.3 as a target in post-traumatic stress disorder (PTSD), building on recent large-scale human genetics research linking variation in the gene encoding CaV2.3 (CACNA1E) to increased risk of the condition. This award complements Lario's previously announced $6m grant by MJFF in 2024,
More news about: Lario Therapeutics
Feb 18, 2026, 20:47 ET NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V.
COMPLAINT ALLEGATION SUMMARY: uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 18, 2026, 17:31 ET Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
may help prevent phenylalanine from entering the brain, and enzyme replacement therapy. Researchers are also investigating the possibility of using gene therapy, which involves injecting new genes to break down phenylalanine.Phenylketonuria Market AnalysisThe
More news about: DelveInsight Business Research, LLP
Feb 18, 2026, 17:00 ET The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
(autosomal dominant), progressive neuromuscular disease that shortens life expectancy and requires life-long care caused by a triplet-repeat in the DMPK gene, resulting in a toxic gain of function mRNA. The disease is highly variable with respect to severity, presentation and age of onset, however, all forms
More news about: Avidity Biosciences, Inc.